Novartis
NVS
S$153.84
Share price
-1.13%
Change (1 day)
3.79%
Change (1 year)
Categories
Novartis AG is a biotechnology and pharmaceutical company based in Basel, Switzerland. Novartis was formed in 1996 from a merger of the two Basel pharmaceutical and chemical companies Ciba-Geigy AG and Sandoz AG. Novartis is one of the largest pharmaceutical companies in the world with sales of USD 47.4 billion in 2019.
Revenue for Novartis (NVS)
Revenue in 2025 (TTM): S$71.08 Billion
According to Novartis's latest financial reports the company's current revenue (TTM 
) is S$68.41 Billion. In 2024 the company made a revenue of S$70.30 Billion an increase over the revenue in the year 2023 that were of S$61.62 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Novartis from 2000 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | S$71.08 B | 1.12% |
| 2024 | S$70.30 B | 14.09% |
| 2023 | S$61.62 B | -7.64% |
| 2022 | S$66.72 B | -6.67% |
| 2021 | S$71.48 B | 8.29% |
| 2020 | S$66.01 B | 0.59% |
| 2019 | S$65.62 B | 0.36% |
| 2018 | S$65.39 B | -2.48% |
| 2017 | S$67.05 B | -6.28% |
| 2016 | S$71.54 B | 0.39% |
| 2015 | S$71.27 B | 0.57% |
| 2014 | S$70.86 B | 0.32% |
| 2013 | S$70.64 B | 0.35% |
| 2012 | S$70.39 B | -8.46% |
| 2011 | S$76.89 B | 15.77% |
| 2010 | S$66.41 B | 4.89% |
| 2009 | S$63.32 B | 3.97% |
| 2008 | S$60.89 B | 9.18% |
| 2007 | S$55.77 B | 3.93% |
| 2006 | S$53.67 B | -0.67% |
| 2005 | S$54.03 B | 17.26% |
| 2004 | S$46.08 B | 9.09% |
| 2003 | S$42.24 B | 4.4% |
| 2002 | S$40.46 B | 12.29% |
| 2001 | S$36.03 B | -0.13% |
| 2000 | S$36.07 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Merck MRK | S$82.17 B | 20.10% | 🇺🇸 USA |
 Pfizer PFE | S$80.29 B | 17.36% | 🇺🇸 USA |
 Johnson & Johnson JNJ | S$114.83 B | 67.85% | 🇺🇸 USA |
 Sanofi SNY | S$60.93 B | -10.94% | 🇫🇷 France |
 GlaxoSmithKline GSK | S$52.17 B | -23.74% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | S$21.35 B | -68.78% | 🇮🇱 Israel |
 Bristol-Myers Squibb BMY | S$61.23 B | -10.50% | 🇺🇸 USA |
 Abbott Laboratories ABT | S$54.43 B | -20.44% | 🇺🇸 USA |
 AstraZeneca AZN | S$70.68 B | 3.31% | 🇬🇧 UK |